Revenues

6 Months Ended

Jun. 30, 2020

Revenues

Revenues

3.     Revenues

As discussed in Note 2, revenues are recognized under guidance within ASC 606 and ASC 808. The following table presents our disaggregated revenue for the periods presented (in thousands):

	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2020		2019		2020		2019
JAKAFI revenues, net	$	473,706	$	409,506	$	933,185	$	785,117
ICLUSIG revenues, net		22,798		24,391		50,046		45,029
PEMAZYRE revenues, net		3,786		—		3,786		—
Total product revenues, net		500,290		433,897		987,017		830,146
JAKAVI product royalty revenues		66,217		56,895		122,550		102,466
OLUMIANT product royalty revenues		25,830		19,140		51,277		35,177
TABRECTA product royalty revenues		706		—		706		—
Total product royalty revenues		92,753		76,035		174,533		137,643
Milestone and contract revenues		95,000		20,000		95,000		60,000
Total revenues	$	688,043	$	529,932	$	1,256,550	$	1,027,789

For further information on our revenue-generating contracts, refer to Note 9 to the condensed consolidated financial statements.